


TargetMI Fact Sheet









Project acronym:

TargetMI

Project name:

A Multi-Omics Approach for Novel Drug Targets, Biomarkers and Risk Algorithms for Myocardial Infarction

Call:

HORIZON-EIC-2022-PATHFINDERCHALLENGES-01

Topic:

HORIZON-EIC-2022-PATHFINDERCHALLENGES-01-03

Type of action:

Horizon EIC Grants

Granting authority:

European Innovation Council and SMEs Executive Agency (EISMEA)

Project number:

101114924

Duration:

60 months (01/10/2023 - 30/09/2028)

Project funding:

€3,999,840.00

Website:

um.edu.mt/projects/targetmi

LinkedIn:

linkedin.com/showcase/targetmi-eu-project

Project description:

Cardiovascular diseases (CVD) encompass various conditions affecting the heart and blood vessels and constitute a major health concern. In myocardial infarction (MI), a sudden disruption in blood flow to the heart leads to cardiac tissue damage or death. Despite research on the genetic, lifestyle, and environmental factors associated with MI, practical applications to prevent it remain limited. Researchers from the University of Malta and the Leiden University Medical Center are collaborating on the TargetMI project, funded by the Pathfinder programme of the European Innovation Council. The consortium is undertaking a high throughput multi-omics analysis on samples and data from the Maltese Acute Myocardial Infarction (MAMI) study including genomic, metabolomic, proteomic, and RNA data, to discover new drug targets and biomarkers for MI and develop novel risk assessment strategies. Machine learning algorithms are being used to analyse the multi-layered data to identify novel biomarkers and risk algorithms, including polygenic risk scores, for early risk prediction in the clinic. Quantitative targeted proteomic assays will be developed for further validation in other cohorts facilitating clinical use. Besides the increase in knowledge on the molecular aetiology of MI, this powerful integrated strategy will bring rapid clinical translation of unprecedented multi-omics data.

Coordinator:

Prof. Stephanie Bezzina Wettinger

Coordinator of TargetMI Project and Principal Investigator at

University of Malta (UM)

Faculty of Health Sciences

Department of Applied Biomedical Science

Msida, MSD2080

Malta

Email: stephanie.bezzina-wettinger@um.edu.mt; targetmi@um.edu.mt

Partner:

Leiden University Medical Center (LUMC)

Contact at LUMC:

Prof. Frits Rosendaal

Principal Investigator, and Chair of the Department of Clinical

Epidemiology at Leiden University Medical Center (LUMC)

LUMC Main Building

Albinusdreef 2

2333 ZA Leiden

Room number C07088

Netherlands

Email: f.r.rosendaal@lumc.nl



Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Innovation Council and SMEs Executive Agency (EISMEA). Neither the European Union nor the granting authority can be held responsible for them.